Andrea Maturana-Ramírez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andrea Maturana-Ramírez has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Peña-Oyarzún
School of Odontology, Faculty of Odontology, Universidad San Sebastián, Santiago, Chile
15 shared publications - Montserrat Reyes
Department of Pathology and Oral Medicine, Faculty of Dentistry, Universidad de Chile, Santiago, Chile
15 shared publications - Vicente A. Torres
Institute for Research in Dental Sciences, Faculty of Dentistry, Universidad de Chile, Santiago, Chile
14 shared publications - Alfredo Criollo
INSERM, U848, Villejuif, France
13 shared publications - Andrew Frederick Geoffery Quest
Cellular Communication Laboratory, Center for Studies on Exercise, Metabolism and Cancer (CEMC), Institute of Biomedical Sciences (ICBM), Faculty of Medicine, University of Chile, Santiago, Chile; Advanced Center for Chronic Diseases (ACCDiS), Faculty of Medicine, University of Chile, Santiago, Chile
13 shared publications - Catalina Kretschmar
Department of Ophthalmology, University of California San Francisco, San Francisco, CA, USA
13 shared publications
Latest Publications
- Open Access
- 1 May 2026
- Published by Springer Nature in BMC Oral Health
- Vol. 26 (1)
Activation of Wnt/β-catenin signaling in histologically non-dysplastic non-homogeneous oral leukoplakia
Oral potentially malignant disorders (OPMD) are lesions that precede oral cancer in approximately 15–40% of cases. Leukoplakia is the most frequent t
- 1 May 2026
- Published by Springer Nature in BMC Oral Health
- Vol. 26 (1)
Open AccessActivation of Wnt/β-catenin signaling in histologically non-dysplastic non-homogeneous oral leukoplakia
Oral potentially malignant disorders (OPMD) are lesions that precede oral cancer in approximately 15–40% of cases. Leukoplakia is the most frequent t
- Open Access
- 6 February 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1522726
Hypovitaminosis D in patients with oral leukoplakia: insights from a cross-sectional study
Introduction: Oral leukoplakia is one of the most frequent oral potentially malignant disorders. The present study aims to compare serum vitamin D levels between patients with and without oral leukoplakia, by smoking habit.Methods: This cross-sectional study involved a group of 45 cases with oral leukoplakia and a control group with 45 individuals. In both groups a pathology report was done, and for leukoplakia a binary classification of low- and high-grade epithelial dysplasia was employed. Serum 25(OH)D3 vitamin D levels, and data on smoking status, age, gender, comorbidities, and clinical and pathological characteristics were collected for both groups.Results: vitamin D levels were lower in the oral leukoplakia group with a median of 19.1 ng/ml, while the control group had a median of 24.8 ng/ml. When subdividing each group by smoking habit, the smoking case group had a median of 19.4 ng/ml (IQR: 15.7-21.5 ng/ml), the non-smoking case group had 18.8 ng/ml (IQR: 13.6-29.2 ng/ml), the smoking control group had 21.8 ng/ml (IQR: 17.5-27.3 ng/ml), and the non-smoking control group had 25.4 ng/ml (IQR: 20.4-32.9 ng/ml) (p<0.05). When comparing serum vitamin D levels, statistically significant differences were found between the smoking case group versus the non-smoking control group and between the non-smoking case group versus the non-smoking control group (p<0.05). Serum vitamin D levels by histopathological diagnosis showed no differences between leukoplakia groups.Discussion: This study shows that serum vitamin D levels were lower in patients with OL compared to those without OL, which was more evident in the smoking group. Patients with OL were previously observed to have hypovitaminosis D, without assessing smoking habits. This finding suggests a possible role of vitamin D deficiency in the development of OL, which could be more marked in smokers. This opens the possibility of future research on vitamin D as a chemopreventive agent in the malignant transformation of OL, and to evaluate the relationship between smoking and hypovitaminosis D.
- 6 February 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1522726
Open AccessHypovitaminosis D in patients with oral leukoplakia: insights from a cross-sectional study
Introduction: Oral leukoplakia is one of the most frequent oral potentially malignant disorders. The present study aims to compare serum vitamin D levels between patients with and without oral leukoplakia, by smoking habit.Methods: This cross-sectional study involved a group of 45 cases with oral leukoplakia and a control group with 45 individuals. In both groups a pathology report was done, and for leukoplakia a binary classification of low- and high-grade epithelial dysplasia was employed. Serum 25(OH)D3 vitamin D levels, and data on smoking status, age, gender, comorbidities, and clinical and pathological characteristics were collected for both groups.Results: vitamin D levels were lower in the oral leukoplakia group with a median of 19.1 ng/ml, while the control group had a median of 24.8 ng/ml. When subdividing each group by smoking habit, the smoking case group had a median of 19.4 ng/ml (IQR: 15.7-21.5 ng/ml), the non-smoking case group had 18.8 ng/ml (IQR: 13.6-29.2 ng/ml), the smoking control group had 21.8 ng/ml (IQR: 17.5-27.3 ng/ml), and the non-smoking control group had 25.4 ng/ml (IQR: 20.4-32.9 ng/ml) (p<0.05). When comparing serum vitamin D levels, statistically significant differences were found between the smoking case group versus the non-smoking control group and between the non-smoking case group versus the non-smoking control group (p<0.05). Serum vitamin D levels by histopathological diagnosis showed no differences between leukoplakia groups.Discussion: This study shows that serum vitamin D levels were lower in patients with OL compared to those without OL, which was more evident in the smoking group. Patients with OL were previously observed to have hypovitaminosis D, without assessing smoking habits. This finding suggests a possible role of vitamin D deficiency in the development of OL, which could be more marked in smokers. This opens the possibility of future research on vitamin D as a chemopreventive agent in the malignant transformation of OL, and to evaluate the relationship between smoking and hypovitaminosis D.
- Open Access
- 1 January 2025
- Published by Medicina Oral, S.L. in Medicina Oral Patología Oral y Cirugia Bucal
- Vol. 30 (1) , e24-e30
Hypovitaminosis D in patients with oral squamous cell carcinoma: Is a risk factor of developing this neoplasia?
Background: Hypovitaminosis D raised a significant public health concern due to its potential association withvar- ious diseases, including Oral Squamous Cell Carcinoma (OSCC). The objective of this study was to compare serum 25(OH)D3 levels between individuals with and without OSCC, and by subgroups based on their smoking habits. Material and Methods: A case-control study was conducted utilizing progressive multicenter recruitment, involving 46 patients with Oral Squamous Cell Carcinoma (OSCC) and 65 controls. Serum levels of 25(OH)D3 were evaluated via electrochemiluminescence. Patients were categorized according to their vitamin D levels into sufficiency, mild deficiency, moderate deficiency, and severe deficiency. Comparative analyses of serum 25(OH)D3 levels were performed between OSCC patients and controls, as well as among subgroups based on their smoking habits. Group comparisons were made with the Mann-Whitney test, and subgroup analyses used the Kruskal-Wallis test. Significance was set atp < 0.05 Results: 91% of participants, including both OSCC patients and controls, exhibited some degree of 25(OH)D3 deficiency. Among them, 71.7% of OSCC patients and 50.7% of controls had serum levels characterized by moderate to severe deficiencies. Patients with OSCC showed lower levels of 25(OH)D3, with medians of 20.2 ng/ml (IQR 9.48), compared to controls, with medians of 24.8 ng/ml (IQR 9.13) (p=0.002). Furthermore, when comparing the medians among the four study groups (smoking and non-smoking controls and smoking and non-smoking patients with OSCC), a significant difference was observed between non-smoking control patients with 25.04 ng/ml (IQR = 9.71) and smoking OSCC patients with 19.65 ng/ml (IQR = 12.14) (p < 0.05). Conclusions: Individuals with oral squamous cell carcinoma (OSCC) exhibited lower serum levels of vitamin D (25(OH)D3) compared to controls, suggesting a potential link between vitamin deficiency and the development of this type of cancer. Vitamin D supplementation could serve as a preventive and therapeutic strategy.
- 1 January 2025
- Published by Medicina Oral, S.L. in Medicina Oral Patología Oral y Cirugia Bucal
- Vol. 30 (1) , e24-e30
Open AccessHypovitaminosis D in patients with oral squamous cell carcinoma: Is a risk factor of developing this neoplasia?
Background: Hypovitaminosis D raised a significant public health concern due to its potential association withvar- ious diseases, including Oral Squamous Cell Carcinoma (OSCC). The objective of this study was to compare serum 25(OH)D3 levels between individuals with and without OSCC, and by subgroups based on their smoking habits. Material and Methods: A case-control study was conducted utilizing progressive multicenter recruitment, involving 46 patients with Oral Squamous Cell Carcinoma (OSCC) and 65 controls. Serum levels of 25(OH)D3 were evaluated via electrochemiluminescence. Patients were categorized according to their vitamin D levels into sufficiency, mild deficiency, moderate deficiency, and severe deficiency. Comparative analyses of serum 25(OH)D3 levels were performed between OSCC patients and controls, as well as among subgroups based on their smoking habits. Group comparisons were made with the Mann-Whitney test, and subgroup analyses used the Kruskal-Wallis test. Significance was set atp < 0.05 Results: 91% of participants, including both OSCC patients and controls, exhibited some degree of 25(OH)D3 deficiency. Among them, 71.7% of OSCC patients and 50.7% of controls had serum levels characterized by moderate to severe deficiencies. Patients with OSCC showed lower levels of 25(OH)D3, with medians of 20.2 ng/ml (IQR 9.48), compared to controls, with medians of 24.8 ng/ml (IQR 9.13) (p=0.002). Furthermore, when comparing the medians among the four study groups (smoking and non-smoking controls and smoking and non-smoking patients with OSCC), a significant difference was observed between non-smoking control patients with 25.04 ng/ml (IQR = 9.71) and smoking OSCC patients with 19.65 ng/ml (IQR = 12.14) (p < 0.05). Conclusions: Individuals with oral squamous cell carcinoma (OSCC) exhibited lower serum levels of vitamin D (25(OH)D3) compared to controls, suggesting a potential link between vitamin deficiency and the development of this type of cancer. Vitamin D supplementation could serve as a preventive and therapeutic strategy.
- Open Access
- 7 November 2024
- Published by California Digital Library (CDL) in Dermatology Online Journal
- Vol. 30 (5)
Idiopathic gingival papillokeratosis with crypt formation: an exclusive entity in the young population?
Idiopathic gingival papillokeratosis with crypt formation (IGPC) is a new and a very rare benign entity, clinically characterized by white-yellowish plaques with papillary architecture located in the upper labial gingiva of adolescent patients. The condition generally exhibits a bilateral symmetrical distribution and is asymptomatic. We report two new cases, one with a classic presentation and the other in an older individual. Through these case reports, we describe and highlight the key clinical and histopathological features associated with IGPC for greater understanding and knowledge by general dentists, oral pathologists, and dermatologists.
- 7 November 2024
- Published by California Digital Library (CDL) in Dermatology Online Journal
- Vol. 30 (5)
Open AccessIdiopathic gingival papillokeratosis with crypt formation: an exclusive entity in the young population?
Idiopathic gingival papillokeratosis with crypt formation (IGPC) is a new and a very rare benign entity, clinically characterized by white-yellowish plaques with papillary architecture located in the upper labial gingiva of adolescent patients. The condition generally exhibits a bilateral symmetrical distribution and is asymptomatic. We report two new cases, one with a classic presentation and the other in an older individual. Through these case reports, we describe and highlight the key clinical and histopathological features associated with IGPC for greater understanding and knowledge by general dentists, oral pathologists, and dermatologists.
- Open Access
- 2 April 2024
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 46 (4) , 3050-3062
Calcitriol Treatment Decreases Cell Migration, Viability and β-Catenin Signaling in Oral Dysplasia
Nearly 90% of oral cancers are characterized as oral squamous cell carcinoma (OSCC), representing the sixth most common type of cancer. OSCC usually evolves from oral potentially malignant disorders that, in some cases, are histologically consistent with a oral dysplasia. The levels of 1α,25 dihydroxyvitamin D3 (1,25-(OH)2D3; calcitriol), the active form of vitamin D3, have been shown to be decreased in patients with oral dysplasia and OSCC. Moreover, treatment with 1,25-(OH)2D3 has been proven beneficial in OSCC by inhibiting the Wnt/β-catenin pathway, a signaling route that promotes cell migration, proliferation, and viability. However, whether this inhibition mechanism occurs in oral dysplasia is unknown. To approach this question, we used dysplastic oral keratinocyte cultures and oral explants (ex vivo model of oral dysplasia) treated with 1,25-(OH)2D3 for 48 h. Following treatment with 1,25-(OH)2D3, both in vitro and ex vivo models of oral dysplasia showed decreased levels of nuclear β-catenin by immunofluorescence (IF) and immunohistochemistry (IHC). Consistently, reduced protein and mRNA levels of the Wnt/β-catenin target gene survivin were observed after treatment with 1,25-(OH)2D3. Moreover, 1,25-(OH)2D3 promoted membranous localization of E-cadherin and nuclear localization of vitamin D receptor (VDR). Functionally, DOK cells treated with 1,25-(OH)2D3 displayed diminished cell migration and viability in vitro.
- 2 April 2024
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 46 (4) , 3050-3062
Open AccessCalcitriol Treatment Decreases Cell Migration, Viability and β-Catenin Signaling in Oral Dysplasia
Nearly 90% of oral cancers are characterized as oral squamous cell carcinoma (OSCC), representing the sixth most common type of cancer. OSCC usually evolves from oral potentially malignant disorders that, in some cases, are histologically consistent with a oral dysplasia. The levels of 1α,25 dihydroxyvitamin D3 (1,25-(OH)2D3; calcitriol), the active form of vitamin D3, have been shown to be decreased in patients with oral dysplasia and OSCC. Moreover, treatment with 1,25-(OH)2D3 has been proven beneficial in OSCC by inhibiting the Wnt/β-catenin pathway, a signaling route that promotes cell migration, proliferation, and viability. However, whether this inhibition mechanism occurs in oral dysplasia is unknown. To approach this question, we used dysplastic oral keratinocyte cultures and oral explants (ex vivo model of oral dysplasia) treated with 1,25-(OH)2D3 for 48 h. Following treatment with 1,25-(OH)2D3, both in vitro and ex vivo models of oral dysplasia showed decreased levels of nuclear β-catenin by immunofluorescence (IF) and immunohistochemistry (IHC). Consistently, reduced protein and mRNA levels of the Wnt/β-catenin target gene survivin were observed after treatment with 1,25-(OH)2D3. Moreover, 1,25-(OH)2D3 promoted membranous localization of E-cadherin and nuclear localization of vitamin D receptor (VDR). Functionally, DOK cells treated with 1,25-(OH)2D3 displayed diminished cell migration and viability in vitro.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Inhibition of PORCN Blocks Wnt Signaling to Attenuate Progression of Oral Carcinogenesis
Specificity of C59 over endogenous Wnt3a signaling in DOK-TC cells
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Inhibition of PORCN Blocks Wnt Signaling to Attenuate Progression of Oral Carcinogenesis
Specificity of C59 over endogenous Wnt3a signaling in DOK-TC cells
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Inhibition of PORCN Blocks Wnt Signaling to Attenuate Progression of Oral Carcinogenesis
Clinical presentation of human oral lesions used as oral carcinogenesis ex vivo modeL
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Inhibition of PORCN Blocks Wnt Signaling to Attenuate Progression of Oral Carcinogenesis
Clinical presentation of human oral lesions used as oral carcinogenesis ex vivo modeL
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Inhibition of PORCN Blocks Wnt Signaling to Attenuate Progression of Oral Carcinogenesis
Effect of C59 on cell invasion in CAL-27 cells
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Inhibition of PORCN Blocks Wnt Signaling to Attenuate Progression of Oral Carcinogenesis
Effect of C59 on cell invasion in CAL-27 cells
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Inhibition of PORCN Blocks Wnt Signaling to Attenuate Progression of Oral Carcinogenesis
Characterization of the in vitro human oral carcinogenesis model
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Inhibition of PORCN Blocks Wnt Signaling to Attenuate Progression of Oral Carcinogenesis
Characterization of the in vitro human oral carcinogenesis model
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Inhibition of PORCN Blocks Wnt Signaling to Attenuate Progression of Oral Carcinogenesis
Clinical presentation of human oral lesions used as oral carcinogenesis ex vivo modeL
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Inhibition of PORCN Blocks Wnt Signaling to Attenuate Progression of Oral Carcinogenesis
Clinical presentation of human oral lesions used as oral carcinogenesis ex vivo modeL